Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Payables: 2021-2024

Historic Payables for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $22.8 million.

  • ARS Pharmaceuticals' Payables rose 201.24% to $49.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.9 million, marking a year-over-year increase of 400.67%. This contributed to the annual value of $22.8 million for FY2024, which is 960.40% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Payables of $22.8 million as of FY2024, which was up 960.40% from $2.2 million recorded in FY2023.
  • ARS Pharmaceuticals' Payables' 5-year high stood at $22.8 million during FY2024, with a 5-year trough of $2.2 million in FY2023.
  • Over the past 3 years, ARS Pharmaceuticals' median Payables value was $4.9 million (recorded in 2022), while the average stood at $10.0 million.
  • In the last 5 years, ARS Pharmaceuticals' Payables tumbled by 56.32% in 2023 and then skyrocketed by 960.40% in 2024.
  • ARS Pharmaceuticals' Payables (Yearly) stood at $6.6 million in 2021, then fell by 25.13% to $4.9 million in 2022, then crashed by 56.32% to $2.2 million in 2023, then soared by 960.40% to $22.8 million in 2024.